Plasma thromboxane and pulmonary artery pressure in neonates treated with extracorporeal membrane oxygenation.
To examine whether neonates with persistent pulmonary hypertension are subject to a thromboxane-mediated exacerbation of their pulmonary hypertension during extracorporeal membrane oxygenator therapy (a form of partial cardiopulmonary bypass), we performed serial measurements of plasma thromboxane B2 and pulmonary artery pressure before, during, and after extracorporeal membrane oxygenation. Pulmonary artery pressure was high before extracorporeal membrane oxygenation, did not increase after the start of this therapy, but began to decrease after 48 hours of extracorporeal membrane oxygenation. During the course of extracorporeal membrane oxygenation, mean pulmonary artery pressure decreased by 50% and mean plasma thromboxane B2 levels decreased by 70%. In addition, serial plasma thromboxane B2 levels were significantly correlated with pulmonary artery pressures in individual infants with a primary diagnosis of meconium aspiration (r = 0.965 to 0.723). We speculate that the decrease in pulmonary artery pressure and plasma thromboxane B2 levels over time may reflect resolution of acute lung injury and that thromboxane B2 may play a role in regulating pulmonary artery pressure in infants with meconium aspiration.
Bui
K C
KC
Division of Neonatology, Children's Hospital National Medical Center, Washington, DC 20010.
Martin
G
G
Kammerman
L A
LA
Hammerman
C
C
Hill
V
V
Short
B L
BL
D004452:Echocardiography; D015199:Extracorporeal Membrane Oxygenation; D006801:Humans; D007231:Infant, Newborn; D010547:Persistent Fetal Circulation Syndrome / Q000097:blood / Q000503:physiopathology / Q000628:therapy*; D011669:Pulmonary Wedge Pressure / Q000502:physiology*; D013929:Thromboxane B2 / Q000097:blood*; D013997:Time Factors
D013929:Thromboxane B2